News
Pertuzumab significantly extends the life of patients with metastatic breast cancer
The final results of the CLEOPATRA clinical trial show that patients with HER2-positive metastatic breast cancer achieve 8-year overall survival of 37% with the targeted treatment combination of pertuzumab + trastuzumab + docetaxel.
Maintenance treatment with oral olaparib in women with BRCA1/2 mutation and relapsed ovarian cancer
In a phase III study published in the journal Lancet Oncology, data on the effectiveness of…
The Benefit of Dabigatran Over Warfarin Is Greater in Patients with Atrial Fibrillation and Diabetes Than in Nondiabetics
As early as 2015, an analysis of the results of the RE-LY study in patients with atrial…
Positive Effect of Diosmin on Venous Disease in Terms of Factors Responsible for Angiogenesis
A study published last year monitored the impact of diosmin on laboratory and clinical parameters…
Diosmin and Hesperidin: What Does Pharmacokinetics Show?
Flavonoids are plant-derived compounds that have a number of beneficial pharmacological effects.…
Obinutuzumab and Early Progression of Patients with Previously Untreated Follicular Lymphoma − Analysis of Data from the GALLIUM Study
The GALLIUM study demonstrated longer progression-free survival (PFS) in patients with previously…
Impact of Dabigatran and Warfarin Treatment on the Risk of Acute Kidney Injury in Patients with Atrial Fibrillation
What clinical characteristics in patients with non-valvular atrial fibrillation may indicate a…
High-Dose Cyclophosphamide in Hard-to-Treat Patients with B-NHL
For hard-to-treat patients with non-Hodgkin lymphoma, cyclophosphamide administered in one or two…
Boy with Hemophilia A with Inhibitor − Case Study with Voting
Presented by: Assoc. Prof. MUDr. Jan Blatný, Ph.D., Department of Pediatric Hematology, University Hospital...
Efficacy of Combination Therapy for Chronic Lymphocytic Leukemia in Patients with Complex Karyotype
A complex karyotype (presence of ≥ 3 chromosomal abnormalities) is a negative prognostic marker in…